Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CTSC | P53634 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CTSH | P09668 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13133357 | 0.82 | SIGMAR1 (0.44) | SIGMAR1CTSCCYP3A4KDM4EMAPT | |
| SCHEMBL3713615 | 0.81 | SIGMAR1 (0.47) | SIGMAR1CYP3A4KDM4EMAPTMCL1 | |
| SCHEMBL9779725 | 0.81 | SIGMAR1 (0.43) | SIGMAR1CTSCCYP3A4KDM4EMAPT | |
| SCHEMBL18775067 | 0.81 | SIGMAR1 (0.43) | SIGMAR1CTSCCYP3A4KDM4EMAPT | |
| SCHEMBL18775058 | 0.80 | SIGMAR1 (0.40) | SIGMAR1CTSCCYP3A4KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL9676562 | 0.80 | CYP3A4 (0.44) | SIGMAR1CTSCCYP3A4KDM4EMAPT | |
| SCHEMBL18775055 | 0.78 | SIGMAR1 (0.38) | SIGMAR1CTSCCYP3A4KDM4EMAPT | |
| SCHEMBL2129593 | 0.77 | CTSC (0.48) | CTSCMAPTMCL1SMN1; SMN2 | |
| SCHEMBL24323636 | 0.77 | SIGMAR1 (0.40) | SIGMAR1CTSCCYP3A4KDM4EMAPT | |
| SCHEMBL18762581 | 0.77 | SIGMAR1 (0.44) | SIGMAR1CTSCCYP3A4KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTSV, CTRL, CTSL | SIGMAR1 4511/4885CTSC 20/4885CYP3A4 614/4885 |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | SIGMAR1 4560/4885CTSC 12/4885CYP3A4 944/4885 |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | SIGMAR1 4560/4885CTSC 12/4885CYP3A4 944/4885 |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | SIGMAR1 4511/4885CTSC 20/4885CYP3A4 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.